Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    0.00 (0.00%)
Bid:
0.00
Ask:
540.00
Spread: 35.00 (6.931%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

26 Jan 2023 07:00

RNS Number : 8918N
Tate & Lyle PLC
26 January 2023
 

26 January 2023 - Tate & Lyle PLC

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months ended 31 December 2022.

 

Headlines

· Third quarter trading consistent with first half of the financial year

· Food & Beverage Solutions top-line momentum continues with revenue up 19%

· Positive outcome from the 2023 calendar year pricing round

· Outlook for the year ending 31 March 2023 unchanged

 

Nick Hampton, Chief Executive said:

"Tate & Lyle continues to perform well with Food & Beverage Solutions delivering another strong quarter of double-digit revenue growth. We have successfully renewed 2023 calendar year customer contracts to recover higher input costs and, despite ongoing economic uncertainty, we continue to deliver against our strategy as a growth-focused speciality food and beverage solutions business."

 

Three months ended 31 December 2022

Revenue1

Food & Beverage Solutions

+19% 

Sucralose

(8%)

Group

+16% 

 

1 Growth in constant currency

 

Divisions

 

Food & Beverage Solutions

Revenue growth benefited from mix management, the pricing through of input cost inflation and acquisitions. In North America, we saw continued revenue growth despite supply chain disruption. Both the regions of Europe and Asia, Middle East, Africa and Latin America delivered strong double-digit revenue growth reflecting good commercial performance and mix management. Volume and revenue performance were similar to the first half of the financial year.

 

Sucralose

Revenue was 8% lower reflecting, as expected, the unwind of orders phased into the first half.

 

Primient minority holding

 

The operational challenges which impacted the first half of the financial year are being addressed, and the 2023 calendar year bulk sweetener pricing round is nearing completion with unit margins returning to pre-inflation levels.

 

Outlook for year ending 31 March 2023 is unchanged

We continue to expect:

· Revenue growth reflecting current top-line momentum

· To offset input cost inflation through strategic mix management, pricing, productivity and cost discipline

· Adjusted profit before tax to be in line with current market expectations2 with stronger profits in Food & Beverage Solutions offsetting lower profits from the minority holding in Primient.

 

 

2 Market expectations as per Factset on 25 January 2023

 

Capital markets event

A capital markets event will be held on Wednesday 8 February 2023 at 14.00 GMT.  The event will be hosted by Nick Hampton, Chief Executive, and will outline Tate & Lyle's strategy, business model, portfolio, markets, and science-led approach which puts it at the centre of the future of food. Registration details will be posted on our website at https://www.tateandlyle.com/investors-hub.

 

END

 

 

 

A third quarter conference call will be held today at 8.00am GMT hosted by Nick Hampton, Chief Executive and Dawn Allen, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the start of the call. Dial in details are as follows:

 

UK dial in number: +44 (0)33 0551 0200

UK toll free number: 0808 109 0700

US dial in number: +1 786 697 3501

US toll free number: +1 866 580 3963

Password: Tate & Lyle

 

14 day conference call replay:

UK replay number: +44 (0)20 8196 1480

US toll free replay number: +1 866 583 1035

Access pin: 8547458#

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle is a world leader in ingredient solutions for healthier food and beverages. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fortification, we develop solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.

We have more than 3,500 employees working in around 57 locations across 39 countries. Tate & Lyle's purpose is Transforming Lives Through the Science of Food and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2022, Tate & Lyle revenue from continuing operations totalled £1.4 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin, Facebook or YouTube

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKPBPFBKDNDB
Date   Source Headline
14th Feb 20222:00 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSTrading Statement
10th Feb 20222:00 pmRNSHolding(s) in Company
9th Feb 20227:00 amRNSDirectorate Change
3rd Feb 20224:00 pmRNSHolding(s) in Company
1st Feb 20223:30 pmRNSHolding(s) in Company
21st Jan 20222:00 pmRNSHolding(s) in Company
17th Jan 20222:00 pmRNSHolding(s) in Company
12th Jan 20224:00 pmRNSHolding(s) in Company
10th Jan 20223:45 pmRNSChange of Registered Office
10th Jan 20223:40 pmRNSDirector/PDMR Shareholding
4th Jan 20224:00 pmRNSBlock listing Interim Review
10th Dec 20212:09 pmRNSHolding(s) in Company
9th Dec 20213:10 pmRNSDirector/PDMR Shareholding
1st Dec 20219:58 amRNSTotal Voting Rights
18th Nov 20214:15 pmRNSHolding(s) in Company
5th Nov 202111:45 amRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSHalf-year Report
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding
11th Aug 20214:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20213:15 pmRNSTotal Voting Rights
29th Jul 202112:45 pmRNSResult of AGM
23rd Jul 20215:00 pmRNSHolding(s) in Company
22nd Jul 20213:15 pmRNSDirector/PDMR Shareholding
16th Jul 20213:30 pmRNSHolding(s) in Company
12th Jul 20214:00 pmRNSHolding(s) in Company
12th Jul 20213:50 pmRNSHolding(s) in Company
12th Jul 20217:00 amRNSTate & Lyle to be re-positioned as growth business
8th Jul 20213:30 pmRNSHolding(s) in Company
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights
27th May 20217:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.